Objective: Hypoxia-ischemia is the leading cause of neurological handicaps in newborns worldwide. Mesenchymal stem cells (MSCs) collected from fresh cord blood of asphyxiated newborns have the potential to regenerate damaged neural tissues. The aim of this study was to examine the capacity for MSCs to differentiate into neural tissue that could subsequently be used for autologous transplantation.
Introduction
Hypoxia-ischemia in newborns leads to acute morbidity, significant mortality and long-term disability. In neonates who develop moderate to severe acute encephalopathy following delivery room resuscitation, approximately half die and a third of the survivors develop long-term neurological deficits.
1,2 From a global perspective, birth asphyxia accounts for more than 800 000 deaths every year, with an equally high number of surviving neonates who suffer from long-term neurological handicaps. 3 Preterm delivery is another major source of neonatal brain injury. 4 Developmental delay and cerebral palsy are frequently seen in preterm infants with intracranial hemorrhage and periventricular leukomalacia, although they also often present in the absence of grossly noticeable brain lesions. 5 Mesenchymal stem cells (MSC) have the capacity for selfrenewal and differentiation into bone, cartilage, neuron and fat cell types. 6 These features are attractive to investigators working to develop cell-based therapies to treat human diseases. Upon exposure to specific growth factors, 7 MSCs are able to differentiate to neuron-like cells, and thus have potential applications in the treatment of neurological diseases. 8 In addition to the direct transdifferentiation into neural cells, MSCs can perform regenerative functions in neural tissues through a number of mechanisms including secretion of trophic factors, inhibition of apoptosis, stimulation of endogenous stem cells and immunomodulation resulting in decreased inflammation. 9 Umbilical cord blood (UCB) contains a high percentage of various stem cell subsets: hemopoeitic, mesenchymal and endothelial stem cells. Therefore, UCB represents a repository of cellular material with outstanding regenerative potential. 10, 11 Because hypoxia is often present in the physiological environment for a variety of stem cell types, researchers have incorporated hypoxic conditions in tissue culturing. 12 Reports have shown that laboratory-induced hypoxia can regulate the proliferation and differentiation of stem cells and, especially when mild, has salutary effects on stem and progenitor cells. 13 On the other hand, severe hypoxia can reduce these processes.
The influence of in vivo hypoxia, as in birth asphyxia, on the proliferation and differentiation of human UCB stem cells has not been studied. Additionally, characterization of stem cells obtained from UCB of preterm infants has not been previously reported. We aimed to examine the biological properties, including the number and viability, of various UCB stem cell populations collected from term neonates who had experienced significant fetal depression in comparison with full-term controls and preterm neonates. Furthermore, we compared the proliferative and neural differentiation properties of MSCs isolated from UCB of these populations. We hypothesized that, when treated in a suitable environment, MSCs in the UCB of preterm and depressed full-term neonates are capable of proliferation and neural differentiation.
Methods

Patients
This prospective study was conducted at Cairo University Medical Center in Cairo, Egypt, during the period from January 2008 to January 2010.
The study population included three groups of newborns. Infants with any of the following criteria were excluded from the study: a) major congenital anomalies, b) previous siblings diagnosed with inborn errors of metabolism, c) family history of hemoglobinopathies or coagulopathies, or d) suspected funisitis, chorioamnionitis, or neonatal sepsis. This study was approved by the Institutional Review Board, and was conducted in compliance with the Declaration of Helsinki and regulations of the University of Cairo. Informed consent for each subject was obtained. Subjects in groups II and III were identified and recruited before the time of delivery, whereas subjects for group I were consented prenatally when fetal compromise was suspected, and enrolled only if neonatal depression occurred after birth.
Blood sampling
Samples of UCB were collected aseptically immediately after delivery and before separation of the placenta. A site at the distal end of the UCB was wiped with gauze to remove any blood, and then wiped three times with iodine swabs toward the placenta at 15 s intervals. A total volume of 20 ml of cord blood was collected using preservative-free heparinized syringes. A sample was also obtained for analysis of a cord blood gas. Samples were collected by the obstetrician in the presence of one of the co-investigators (DA) who was responsible for ensuring compliance with the specified protocol.
Separation of mononuclear cells UCB was diluted to a 1:2 ratio with phosphate buffer saline, layered over Ficoll Hypaque (density 1.077, Biochrom KG, Berlin, Germany) for density gradient separation and centrifuged at 1800 r.p.m. for 20 min. Collected mononuclear cells were washed twice with phosphate buffer saline, resuspended and counted. Viability testing was done using trypan blue exclusion test.
Flow cytometric analysis
To enumerate the various stem cell subsets in UCB, we used Coulter Epics Elite flow cytometer (Beckman Coulter, Miami, FL, USA), with stem cell markers including CD34 and CD38 (R&D, Minneapolis, MN, USA and Dako, Glostrup, Denmark). Single-and dual-expression CD34 and CD38 were assessed for hematopoietic commitment and reduction of plasticity. CD34 monoclonal antibody was phycoerythrin-labeled and CD38 was fluorescein isothiocyanate labeled. Cells positive for both markers (dual expression) were located in the upper right quadrant of the output histogram.
MSC isolation
Mononuclear cells were incubated for 2 weeks and subcultured in a complete medium containing nerve growth factor in fibronectincoated flasks. 15 After 2 to 4 weeks, viability was tested and immunohistochemical staining was done to examine neural differentiation.
Assessment of proliferative capacity of UCB MSCs DNA index was done for cultured cells to assess their proliferative capacity using flow cytometry. DNA indexing was related to half of the DNA content in human cells (DNA ¼ 1n); and cells were grouped according to the DNA content into three types as follows: a) normal quiescent cells that contain DNA ¼ 2n, b) cycling cells that contain DNA >2n, but <4n, and c) apoptotic cells that contain DNA <2n.
Immunohistochemistry
Microscopic examination was performed after preparation with primary antibodies from neural stem cell functional identification kit (StemCell Technologies, Vancouver, Canada; catalog number 
Results
A total of 55 subjects were included in the three study groups, with 27, 14 and 14 subjects in groups I, II and III, respectively. Deliveries in group I, asphyxia group, were complicated by severe fetal distress (n ¼ 15), meconium-stained amniotic fluid (n ¼ 9) and eclampsia (n ¼ 3). Groups I and II were similar in gestational age, and there was a nonsignificant trend for male predominance in group I (67 vs 43%, P ¼ 0.14). Results of the blood gases measured in UCB are presented in Table 1 . When compared with the other two groups, group I had significantly lower pH and PO 2 (P<0.001 and P ¼ 0.04, respectively) and higher PCO 2 (P ¼ 0.01). In group I, cord blood pH was <7.15 in 17 subjects; 4 of them had pH <7, whereas none in the other two groups had such significant acidemia. Delivery room resuscitation for group I included positive pressure ventilation (n ¼ 15), endotracheal intubation (n ¼ 6), chest compressions (n ¼ 2) and administration of inotropic medication (n ¼ 2). Neurological examination of the newborns in group I showed hypoxic-ischemic encephalopathy in 17 subjects (63%), which was mild (n ¼ 10), moderately-severe (n ¼ 5) or severe (n ¼ 2), using the Sarnat's grading system for encephalopathy. 16 Abnormal neurological findings included: convulsions (n ¼ 8, 30%), hypertonia (n ¼ 8, 30%), hypotonia (n ¼ 3, 11%), abnormal reflexes (n ¼ 17, 63%) and impaired consciousness (n ¼ 6, 22%). There were no neurological abnormalities in group II. Physical and neurobehavioral examinations of group III were appropriate for their gestational age.
Mononuclear cells and viability results among studied group
There was a borderline significant difference between the three groups (P ¼ 0.051), with the greatest cell count in group II and the least count in group I. Viability tests were done after culture that demonstrated no significant difference between groups (P ¼ 0.54). Viability in each of the three studied groups ranged between 98 and 100% ( Table 2) .
Flow cytometric analysis of Mononuclear cells
Single-and dual-CD34 (hemopoeitic stem cell marker) and CD38 (commitment marker) expression were done to assess stemness and ongoing differentiation. CD38 expression was the highest in group II (P<0.001), but did not differ between groups I and III. CD34 and dual expression did not differ among the three groups ( Table 2) .
MSCs identification
Examination of the culture flasks under an inverted microscope revealed typical fibroblast-like morphology. MSCs showed ability to differentiate into chondrocyte, osteoblast and adipocyte lineages, and expressed typical immunophenotype (i.e., positive for CD44, CD90, CD105; negative for CD45, CD34).
To examine the proliferative capacity, DNA index was done following the culture of cells. The vast majority of cells (93 to 98%) were quiescent. Few cells were cycling in each of the three groups, without significant difference among groups (P ¼ 0.51).
Morphological evaluation of neural differentiation
Examination of MSC subjected to nerve growth factor medium revealed the appearance of dendrites and star-shaped cells. Immunohistochemical studies were done on 35 subjects (n ¼ 16, 11 and 8 in groups I, II and III, respectively). Thirteen (37%) subjects demonstrated neural differentiation into all three neural cell types (astrocytes, neurons and oligodendrocytes) in more than 80% of MSCs; of them, 11 subjects belonged to group I. Additionally, 14 subjects (40%) showed differentiation in 50 to 80% of MSCs; of them, 5 subjects were in group 1, and 8 Cord mesenchymal stem cells following asphyxia H Aly et al were in group II. Undifferentiated cells were seen in eight subjects; the majority of them (seven out of eight) were preterm infants in group III. Therefore, group I had the most and group III had the least neuronal differentiation (P ¼ 0.01; Figures 1) .
Discussion
This study demonstrates that MSCs in the cord blood collected from hypoxic infants showed comparable viability and cell cycle state as normoxic infants whether term or preterm. Almost 90% of the cells in all groups were quiescent as indicated by the DNA index. The potential for in vitro neural differentiation was best observed in hypoxic infants. Complete MSCs differentiation to astrocytes, neurons and oligodendrocytes occurred in this group (69%), whereas it was hardly identified in healthy term (18%) or preterm neonates (0%). Viability of MSCs, collected from UCB in this study, was not compromised by perinatal asphyxia. In vivo stem cells derived from early-stage blastocysts have a low oxygen environment. This hypoxia maintains pluripotency and minimizes spontaneous differentiation. 17, 18 Thus, the link between hypoxia in the microenvironment and the capability of MSCs to maintain viability, as well as ability to proliferate and differentiate, led researchers to use hypoxic environments in vitro.
19
To the best of our knowledge, this work is the first to test the ability of cord blood MSCs derived from asphyxiated neonates to differentiate into neural lineage. Previous work examined the ability of MSCs to proliferate and differentiate when exposed to in vitro hypoxic conditions. 20, 21 Infusion of MSCs at 3 and 10 days post-hypoxic-ischemic injury was recently shown to enhance cell proliferation, survival and differentiation. 10 It was originally hypothesized that regeneration occurs directly by incorporation of MSC-derived neurons and oligodendrocytes to restore damage. 22, 23 However, there is now evidence to support that treatment with MSCs after hypoxic-ischemic encephalopathy results in enhanced endogenous cell proliferation and differentiation. In addition, MSC treatment may also be associated with the inhibition of injurious processes. [24] [25] [26] The increased proliferative capacity of MSCs under low O 2 tension is thought to be due to increased expression of hypoxia inducible factor-1a that promotes self renewal and inhibits apoptosis of cells, whereas increased O 2 tension promotes differentiation or apoptosis. 27 We found that more than 90% of the cells in all groups were quiescent as indicated by the DNA index. A recent study reported a significantly reduced rate of proliferation in severely hypoxic medium with the accumulation of G1 phase cells, 28 which is similar to our findings. Others 20, 21 have demonstrated that UCB-derived human MSCs can adapt to a physiologically hypoxic environment by altering their energy consumption and metabolism.
We observed complete MSCs differentiation to astrocytes, neurons and oligodendrocytes, mostly in the term asphyxia neonates, but rarely in healthy term neonates or preterm neonates. It is possible that the release of different inflammatory cytokines in response to hypoxia could promote the differentiation of MSCs to the appropriate cell line needed for tissue repair. Such response and differentiation is not limited to the nervous system. In patients with osteoarthritis, for example, hypoxia has been demonstrated to stimulate the commitment of stem cells in the infrapatellar fat pad to chondrogenesis. 29 Although hypoxia stimulates MSCs to differentiate, in general, the determination of cell lineage is dependent on the environmental milieu through mechanisms that are still incompletely understood. It is equally unclear why the absence of in vitro neural differentiation was observed in cells Cord mesenchymal stem cells following asphyxia H Aly et al collected from preterm infants. It is likely that the in vivo cerebral environment differs by gestational age. This is evidenced by the diverse response between term and preterm infants to hypoxicischemic insults, in which neuronal injury predominates in term infants, whereas oligodendroglial and white-matter injury manifest in premature infants. 30 Cell therapy has been described as a promising treatment for certain neurodegenerative diseases, as well as various forms of acute injury to the spinal cord and brain. 31 MSCs or multipotent mesenchymal stem cells (MSCs) may serve as a substrate for regenerative stem cell therapy due to their ability to self renew, differentiate into multiple tissues 32 and immunomodulate. 33 Under certain conditions, stem cells from fresh cord blood are able to differentiate into neurons, microglial cells and astrocytes. Animal models have shown that treatment with fresh cord blood resulted in improvements in the progression of neurological disorders including stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease and spinal cord injuries. Further, improved bone healing was noted. 34 Intracerebral transplantation of MSCs derived from human UCB was shown to enhance the functional recovery of neonatal rats with hypoxic-ischemic brain injury. 35 Although this study provides preliminary data supporting the promise of human UCB MSCs for cell-based repair after perinatal brain injury, it is recognized that it is premature to draw conclusions about the practicality and the efficacy of using these cells for autologous transplantation in the vulnerable neonatal population.
We found that more than 90% of the cells in all groups were quiescent as indicated by the DNA index. A recent study reported a significantly reduced rate of proliferation in severe hypoxic medium with accumulation of G1 phase cells 28 that is similar to our findings, whereas others 20,21 demonstrated the umbilical cordderived human MSCs to adapt their energy consumption and metabolism when cultured in a physiologically appropriate hypoxic environment.
Fresh cord blood is a promising source of non-hematopoietic stem cells. Among others, it contains endothelial cells and mesenchymal stromal cells. 36 UCB is more readily available than bone marrow. MSCs can be isolated from UCB within 2 to 3 working days, favorable for time-sensitive situations. Because of the immunological immaturity of the cells, cord blood is better tolerated than bone marrow, although being equally safe and effective. 14, 37 In certain circumstances, cord blood can be transplanted successfully even if the donor and the recipient are not a perfect match; this substantially widens the range of patients who are able to receive a transplant. 14 
Conclusions
This study is the first to demonstrate that perinatal hypoxia influences the potential for MSCs to differentiate into neural cells when later exposed to the appropriate in vitro conditions. Our findings provide evidence for the multipotential nature of UCB-derived MSCs, and support the rationale for future studies in animal models of hypoxic-ischemic encephalopathy and Cord mesenchymal stem cells following asphyxia H Aly et al eventual early human trials of autologous MSC-based therapy in neonates with hypoxic-ischemic encephalopathy.
